BUZZ-China's AIM Vaccine jumps on expectation of narrower annual loss

Reuters03-17

** Shares of vaccine developer AIM Vaccine 6660.HK jump 11.6% to HK$3.93

** Co expects net loss of 250 mln to 290 mln yuan ($34.54 mln - $40.07 mln) for 2024, compared to net loss of 1.95 bln yuan in 2023, with revenue of 1.25 bln - 1.3 bln yuan as compared to 1.19 bln yuan a year ago

** Says lower net loss due to decrease in the amount of significant asset impairment losses, and an increase in revenue from higher HBV vaccination revenue

** Hang Seng Commerce & Industry Index .HSNC gains 0.9%, Hang Seng Index .HSI rises 1.3%

** Stock down 38.1% YTD

($1 = 7.2376 Chinese yuan renminbi)

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment